Indivior Pharmaceuticals, Inc. (SPUN)
NASDAQ: SPUN · Real-Time Price · USD
36.28
+0.91 (2.57%)
At close: Nov 2, 2026
Indivior Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,374 | 1,239 | 1,188 | 1,093 | 901 | 791 | |
Revenue Growth | 16.44% | 4.29% | 8.69% | 21.31% | 13.91% | 22.26% |
Cost of Revenue | 196 | 198 | 190 | 174 | 151 | 127 |
Gross Profit | 1,178 | 1,041 | 998 | 919 | 750 | 664 |
Selling, General & Admin | 500 | 578 | 600 | 565 | 469 | 425 |
Research & Development | 37 | 80 | 107 | 116 | 74 | 52 |
Other Operating Expenses | -4 | -4 | -5 | -9 | -8 | - |
Operating Expenses | 533 | 654 | 702 | 672 | 535 | 477 |
Operating Income | 645 | 387 | 296 | 247 | 215 | 187 |
Interest Expense | -16 | -45 | -41 | -35 | -27 | -18 |
Interest & Investment Income | 15 | 22 | 23 | 43 | 19 | 1 |
Other Non Operating Income (Expenses) | -3 | - | - | 1 | 1 | 3 |
EBT Excluding Unusual Items | 641 | 364 | 278 | 256 | 208 | 173 |
Merger & Restructuring Charges | -81 | -121 | -53 | - | - | 1 |
Gain (Loss) on Sale of Investments | -1 | -1 | -9 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 20 |
Legal Settlements | -3 | -3 | -195 | -239 | -296 | -14 |
Other Unusual Items | -18 | - | - | - | - | -2 |
Pretax Income | 538 | 239 | 20 | -145 | -88 | 190 |
Income Tax Expense | 88 | 29 | 13 | -19 | -44 | -15 |
Net Income | 450 | 210 | 7 | -126 | -44 | 205 |
Net Income to Common | 450 | 210 | 7 | -126 | -44 | 205 |
Net Income Growth | 248.84% | 2900.00% | - | - | - | - |
Shares Outstanding (Basic) | 122 | 125 | 132 | 137 | 139 | 146 |
Shares Outstanding (Diluted) | 127 | 128 | 133 | 137 | 139 | 152 |
Shares Change | -0.98% | -3.76% | -2.92% | -1.44% | -8.52% | 3.66% |
EPS (Basic) | 3.69 | 1.68 | 0.05 | -0.92 | -0.32 | 1.41 |
EPS (Diluted) | 3.55 | 1.64 | 0.05 | -0.92 | -0.32 | 1.35 |
EPS Growth | 250.94% | 3180.00% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 31 | -93 | 7 | -308 | -9 | 349 |
Free Cash Flow Per Share | 0.24 | -0.73 | 0.05 | -2.25 | -0.07 | 2.30 |
Gross Margin | 85.73% | 84.02% | 84.01% | 84.08% | 83.24% | 83.94% |
Operating Margin | 46.94% | 31.24% | 24.92% | 22.60% | 23.86% | 23.64% |
Profit Margin | 32.75% | 16.95% | 0.59% | -11.53% | -4.88% | 25.92% |
Free Cash Flow Margin | 2.26% | -7.51% | 0.59% | -28.18% | -1.00% | 44.12% |
EBITDA | 652 | 397 | 309 | 259 | 228 | 199 |
EBITDA Margin | 47.45% | 32.04% | 26.01% | 23.70% | 25.30% | 25.16% |
D&A For EBITDA | 7 | 10 | 13 | 12 | 13 | 12 |
EBIT | 645 | 387 | 296 | 247 | 215 | 187 |
EBIT Margin | 46.94% | 31.24% | 24.92% | 22.60% | 23.86% | 23.64% |
Effective Tax Rate | 16.36% | 12.13% | 65.00% | - | - | - |
Advertising Expenses | - | 124 | 68 | 53 | 52 | - |